Cyclacel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Bio Green Med Solution

11/05/2023 22:46

* Cyclacel Pharmaceuticals Inc  CYCC.OQ  reported a
quarterly
adjusted loss of 47 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 66 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cyclacel Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 47 cents​.
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cyclacel Pharmaceuticals Inc shares had fallen by 0.6%
this
quarter and lost 14.9% so far this year.
    * The company reported a quarterly loss of $5.8 million.
    * Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $13.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:46 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.66          -0.47          Beat
 Dec. 31 2022      -0.48          -0.60          Missed
 Sep. 30 2022      -0.56          -0.42          Beat
 Jun. 30 2022      -0.63          -0.46          Beat